SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-017417
Filing Date
2017-08-11
Accepted
2017-08-11 16:31:15
Documents
53
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q Q2'2017 eigr-10q_20170630.htm 10-Q 1603484
2 EX-31.1 eigr-ex311_7.htm EX-31.1 16843
3 EX-31.2 eigr-ex312_9.htm EX-31.2 16904
4 EX-32.1 eigr-ex321_8.htm EX-32.1 5739
  Complete submission text file 0001564590-17-017417.txt   5271658

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT eigr-20170630.xml EX-101.INS 1153752
6 XBRL TAXONOMY EXTENSION SCHEMA eigr-20170630.xsd EX-101.SCH 38481
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE eigr-20170630_cal.xml EX-101.CAL 34653
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eigr-20170630_def.xml EX-101.DEF 129617
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20170630_lab.xml EX-101.LAB 283634
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20170630_pre.xml EX-101.PRE 213405
Mailing Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306
Business Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36183 | Film No.: 171025524
SIC: 2836 Biological Products, (No Diagnostic Substances)